Abstract
Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75% of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50% of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression.
Original language | English (US) |
---|---|
Pages (from-to) | 188-197 |
Number of pages | 10 |
Journal | Cellular Immunology |
Volume | 270 |
Issue number | 2 |
DOIs | |
State | Published - 2011 |
Externally published | Yes |
Keywords
- 4T1 mammary carcinoma
- Brother of regulator of imprinted sites (BORIS)
- Dendritic cell (DC)-based vaccine
- Immunotherapy of breast cancer
- Myeloid derived suppressor cells (MDSC)
- Tumor promoting transcription factor
ASJC Scopus subject areas
- Immunology